Lilly's oral GLP-1, Foundayo , was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Lilly's oral GLP-1, Foundayo , demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Lilly's EloraTZP delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
New Phase 3b data show Lilly's EBGLYSS delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Lilly's Zepbound was associated with more weight loss than Wegovy HD in a new indirect treatment comparison
Lilly's Foundayo 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
FDA approves Lilly's Olumiant for pediatric patients 12 years of age and older with severe alopecia areata
U.S. Food and Drug Administration approves Lilly's Onswik , a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
U.S. FDA approves Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Market One Minute Feature on BNN Bloomberg: Omega Pacific Resources Drills to Expand Gold Discovery in BC's Toodoggone
QIMC Engages Global Seismic Processing Leader Earth Signal to Advance Nova Scotia Hydrogen and Helium Multi-Gas Pilot Production Pathway
